Minority News
The world you see depends upon the news you get. ®
April 30, 2024
WEF Special Meeting Concludes in Riyadh With World Leaders Calling for Clear, Irreversible Path to Peace and Prosperity as Top G  •     •   SHATTERPROOF AND ANTHEM BLUE CROSS FOUNDATION PARTNER TO REDUCE HEALTHCARE STIGMA AROUND A SUBSTANCE USE DISORDER IN CALIFORNIA   •     •   Joby Expands California Manufacturing Facility, Rolls Second Aircraft Off Production Line   •     •   Coursera Reports First Quarter 2024 Financial Results   •     •   Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship   •     •   EY Announces Avelo Airlines Founder Andrew Levy as an Entrepreneur Of The Year® 2024 Gulf South Award Finalist   •     •   Rock Tech Lithium announces feedstock supply agreement with C&D Logistics (Qingdao) Co., Ltd., a supply chain enterprise und  •     •   Matchbox Launches New Mercedes-Benz Die-Cast Car to Celebrate the Reveal of the All-New Electric G-Class   •     •   THE KIDS MENTAL HEALTH FOUNDATION HOSTS INAUGURAL "FAMILY DAY CELEBRATION" TO KICK OFF MENTAL HEALTH AWARENESS MONTH   •     •   Athletes, Entrepreneurs and Investors Gather in Detroit During the Draft to Discuss Working Together to Build Community and Gene  •     •   Scientific leaders gather at global summit in Denmark to advance knowledge and solutions on health and sustainability   •     •   Welltower Reports First Quarter 2024 Results   •     •   Gecko Robotics and Al Masaood Energy Partner to Help ADNOC Gas Revolutionize Asset Operations and Maintenance with AI and Advanc  •     •   WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment   •     •   The Grant Sherpa and WorkForce Strategies International Announce a Revolutionary Solution to Address the Skills Gap Crisis   •     •   IEI Announces Groundbreaking e-Paper Display Solution for Sustainable Communication   •     •   MemorialCare Miller Children's & Women's Hospital Long Beach Named Official Children's Hospital of Angels Baseball & Log  •     •   Marin Software Launches AI-powered Anomaly Detector to Unlock Growth in Performance Marketing Campaigns   •     •   POTTS LAW FIRM: WEST TEXAS WOMAN FILES MULTI MILLION DOLLAR LAWSUIT AGAINST TRUCKING COMPANY   •     •   Hyliion and Victory Execute Letter of Intent to Deploy up to 10 KARNO™ Generators to H2 Energy Group   •  
HOME SEARCH SUBSCRIBE CONTACT

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower

EMERYVILLE, Calif. , April 17 /Businesswire/ - NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.

“We started 2024 with strong revenue growth from our core eyecare business while reducing marketing spend by capitalizing on our e-marketing expertise,” said Justin Hall, CEO of NovaBay. “Investing in direct-to-consumer marketing to leverage our clinical pedigree is a modern approach to the pharmaceutical industry’s traditional sales model. We are pleased that our social media programs are efficiently establishing consumer trust in the Avenova brand as eyecare professionals engage with new potential customers to share their personal experience, knowledge and recommendations.”

NovaBay also announces the expansion of its Avenova Ambassador initiative, an efficient omni-channel, influencer-based social media program. This initiative involves content collaborations and affiliate partnerships with key medical influencers including optometrists and ophthalmologists, collectively known as Avenova “Docfluencers,” as well as consumer-based influencers in strategic growth categories such as beauty and health and wellness. The Avenova Ambassador initiative is proven to be successful in reaching new customers while helping build brand awareness and loyalty via social media channels including TikTok, Instagram, YouTube, Facebook and Pinterest, as well as in email campaigns.

About NovaBay Pharmaceuticals, Inc.

NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is available directly to consumers through online distribution channels such as Amazon.com. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the United States.

Forward-Looking Statements

This release contains information about management's view of the Company's future expectations, plans and prospects that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the fact that they do not relate strictly to historic or current facts. Such forward-looking statements are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, commercial progress, current and potential future sales channels, and any future revenue, and the timing of such revenue, that may result from these marketing efforts, as well as generally the Company’s expected future financial results. These statements involve risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by these forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the Company’s products not being able to penetrate one or more targeted markets and the Company’s ability to continue as a going concern and revenues (or the execution on capital raise opportunities) not being sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K/Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay Informed on NovaBay’s Progress

Like us on Facebook

Follow us on X

Connect with NovaBay on LinkedIn

Visit NovaBay’s Website

Avenova Purchasing Information

For NovaBay Avenova purchasing information:

Please call 800-890-0329 or email sales@avenova.com

Avenova.com